Scott Koenig - Concepedia

Author

Scott Koenig

Also Known As

Haynes, Barton F., Köenig, Sabine, S Koenig, S. KOENIG, S. Koenig, S.M. Koenig, SCOTT KOENIG, Scott Koenig, Tomaras, Georgia D.

210

Publications

17.9K

Citations

H-Index

117

Concepts

All Affiliations

MacroGenics (United States)National Institutes of Health National Institute of Allergy and Infectious Diseases Memorial Sloan Kettering Cancer Center Altimmune (United States)

About

Scott Koenig is an author at MacroGenics (United States) specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	52	11.6K
2	Health Sciences	2	2	29
3	Natural Sciences	2	2	160
4	Public Health	1	1	118
5	Social Sciences	1	1	141

Scott Koenig

Publications

16.7K

Citations

H-Index

Page 1

	Year	Citations
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone Akio Adachi, Howard E. Gendelman, Scott Koenig, Journal of Virology Primary ImmunodeficiencyViral ReplicationHuman RetrovirusPathogenesisImmunology	1986	2.9K
Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy Scott Koenig, Howard E. Gendelman, Jan M. Orenstein, Science Viral ReplicationBrain MacrophagesAids VirusViral PathogenesisImmunology	1986	1.7K
Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus Syd Johnson, Cynthia N. Oliver, Gregory A. Prince, The Journal of Infectious Diseases	1997	636
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease Steven Jacobson, Hisatoshi Shida, Dale E. McFarlin, Nature Primary ImmunodeficiencyAutoimmune DiseaseCd8+ Cytotoxic TNeurovirologyImmunodeficiencies	1990	608
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial Nicole Sherry, William Hagopian, Johnny Ludvigsson, The Lancet Type 1Disease ManagementDiabetes ManagementHealth PolicyDiabetes	2011	484
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. T M Folks, D. Powell, Marilyn M. Lightfoote, The Journal of Experimental Medicine Viral ReplicationViral ImmunityViral PathogenesisImmunologyPathology	1986	415
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression Scott Koenig, Anthony J. Conley, Yambasu A. Brewah, Nature Medicine Primary ImmunodeficiencyAutoimmune DiseaseHiv-1-specific Cytotoxic TMedicineHuman Retrovirus	1995	380
Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against <i>Streptococcus pneumoniae</i> Infection Theresa M. Wizemann, Jon H. Heinrichs, John E. Adamou, Infection and Immunity Humoral ResponseImmunologyS. PneumoniaeBacterial PathogensCross-protection	2001	351
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, JAMA Oncology	2021	336
Vaccination with FimH Adhesin Protects Cynomolgus Monkeys from Colonization and Infection by Uropathogenic<i>Escherichia coli</i> Solomon Langermann, Roland Möllby, Jeanne E. Burlein, The Journal of Infectious Diseases	2000	330

Page 1